ProCE Banner Activity

Assessing EGFR Mutation and MET Amplifications Status in NSCLC

Slideset Download
Download this slideset on assessing EGFR and MET amplifications mutation status in patients with NSCLC.

Released: November 22, 2021

Expiration: November 21, 2022

No longer available for credit.

Share

Faculty

Alexander Spira

Alexander Spira, MD, PhD, FACP

Director                                                                                                                                                                        NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director                                                                                                                                                                    Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Alexander Spira, MD, PhD, FACP

Director                                                                                                                                                                        NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director                                                                                                                                                                    Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Alexander Spira, MD, PhD, FACP, has disclosed that he has received funds for research support from AbbVie, ADCT, Amgen, Arch Therapeutics, Astellas, Astex Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Ignyta, Incyte, Janssen, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Mirati Therapeutics, Newlink Genetics, Novartis, Plexxikon, Roche, Rubius, Takeda, Trovagene; consulting fees from Amgen, Array Biopharma, AstraZeneca, Bristol-Myers SquibbGritstone, Incyte, Janssen, Jazz Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, and Takeda.